{
    "nct_id": "NCT05827614",
    "official_title": "An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications",
    "inclusion_criteria": "* Locally advanced or metastatic non-resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists,\n* Single agent arm: Evidence of oncogene amplification,\n* BBI-355 combination with erlotinib arm: Evidence of amplification of wildtype EGFR,\n* BBI-355 combination with futibatinib arm: Evidence of amplification of wildtype FGFR1, FGFR2, FGFR3, or FGFR4,\n* Availability of FFPE tumor tissue, archival or newly obtained,\n* Measurable disease as defined by RECIST Version 1.1,\n* Adequate hematologic function,\n* Adequate hepatic and renal function,\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1,\n* Other inclusion criteria per study protocol.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Well-known tumor activating oncogene mutations or fusions,\n* Prior exposure to CHK1 inhibitors,\n* BBI-355 combination with erlotinib arm: Prior exposure to EGFR inhibitors,\n* BBI-355 combination with futibatinib arm: Prior exposure to FGFR inhibitors,\n* Hematologic malignancies,\n* Primary CNS malignancy, leptomeningeal disease, or symptomatic active CNS metastases, with exceptions per study protocol,\n* Prior or concurrent malignancies, with exceptions per study protocol,\n* History of HBV, HCV, or HIV infection,\n* Clinically significant cardiac condition,\n* Active or history of interstitial lung disease (ILD) or pneumonitis, or history of ILD or pneumonitis requiring steroids or other immunosuppressive medications,\n* QTcF > 470 msec,\n* Prior organ allograft transplantations or allogeneic peripheral blood stem cell/bone marrow transplantation,\n* Other exclusion criteria per study protocol.",
    "miscellaneous_criteria": "Key"
}